Dashboard
Manage Tickers

FATEFATE THERAPEUTICS INC

Nasdaq fatetherapeutics.com


$ 3.46 $ 0.06 (1.77 %)    

Monday, 09-Sep-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 3.45
$ 3.41
$ 3.45 x 300
$ 3.46 x 699
$ 3.40 - $ 3.52
$ 1.63 - $ 8.83
831,987
na
392.88M
$ 1.53
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-26-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-03-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-03-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-04-2021 06-30-2021 10-Q
14 05-05-2021 03-31-2021 10-Q
15 02-24-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-02-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 03-05-2019 12-31-2018 10-K
24 11-01-2018 09-30-2018 10-Q
25 08-06-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-05-2018 12-31-2017 10-K
28 11-01-2017 09-30-2017 10-Q
29 08-14-2017 06-30-2017 10-Q
30 05-15-2017 03-31-2017 10-Q
31 03-16-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 03-03-2016 12-31-2015 10-K
36 11-03-2015 09-30-2015 10-Q
37 08-05-2015 06-30-2015 10-Q
38 05-07-2015 03-31-2015 10-Q
39 03-12-2015 12-31-2014 10-K
40 11-12-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-neutral-on-fate-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Neutral on ...
08/22/2024 11:34:49

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $...

needham-reiterates-hold-on-fate-therapeutics
Needham Reiterates Hold on Fate Therapeutics
08/14/2024 09:30:25

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) with a Hold.

fate-therapeutics-q2-2024-adj-eps-033-beats-048-estimate-sales-680m-beat-141m-estimate
Fate Therapeutics Q2 2024 Adj EPS $(0.33) ...
08/13/2024 20:09:30

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0...

why-charles-schwab-shares-are-trading-lower-by-over-7-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Charles Schwab Shares Are Trading Lowe...
07/16/2024 17:06:26

unitedhealth-posts-better-than-expected-earnings-joins-angiodynamics-bank-of-america--and-other-big-stocks-moving-higher-on-tuesday
UnitedHealth Posts Better-Than-Expected Ea...
07/16/2024 15:09:23

expert-outlook-fate-therapeutics-through-the-eyes-of-9-analysts
Expert Outlook: Fate Therapeutics Through ...
06/17/2024 20:00:28

this-best-buy-analyst-turns-bullish-here-are-top-5-upgrades-for-monday
This Best Buy Analyst Turns Bullish; Here ...
06/17/2024 13:51:03

fate-therapeutics-shares-are-trading-higher-after-piper-sandler-upgraded-the-stock-from-neutral-to-overweight-and-raised-its-price-target-from-4-to-6
Fate Therapeutics shares are trading highe...
06/17/2024 12:56:20

piper-sandler-upgrades-fate-therapeutics-to-overweight-raises-price-target-to-6
Piper Sandler Upgrades Fate Therapeutics t...
06/17/2024 10:08:43

Piper Sandler analyst Edward Tenthoff upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Overweight and raises the pri...

alibaba-to-rally-over-13-here-are-10-top-analyst-forecasts-for-thursday
Alibaba To Rally Over 13%? Here Are 10 Top...
05/16/2024 12:20:20

hc-wainwright--co-maintains-neutral-on-fate-therapeutics-lowers-price-target-to-5
HC Wainwright & Co. Maintains Neutral on F...
05/16/2024 11:39:37

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the p...

canaccord-genuity-maintains-buy-on-fate-therapeutics-lowers-price-target-to-9
Canaccord Genuity Maintains Buy on Fate Th...
05/10/2024 18:37:42

Canaccord Genuity analyst Bill Maughan maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and lowers the price target from...

bmo-capital-maintains-market-perform-on-fate-therapeutics-lowers-price-target-to-6
BMO Capital Maintains Market Perform on Fa...
05/10/2024 15:16:19

BMO Capital analyst Etzer Darout maintains Fate Therapeutics (NASDAQ:FATE) with a Market Perform and lowers the price target...

wedbush-maintains-neutral-on-fate-therapeutics-lowers-price-target-to-5
Wedbush Maintains Neutral on Fate Therapeu...
05/10/2024 13:38:07

Wedbush analyst David Nierengarten maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the price target from...

piper-sandler-maintains-neutral-on-fate-therapeutics-lowers-price-target-to-4
Piper Sandler Maintains Neutral on Fate Th...
05/10/2024 13:18:21

Piper Sandler analyst Edward Tenthoff maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the price target f...

fate-therapeutics-q1-2024-gaap-eps-047-inline-sales-1925m-beat-1114m-estimate
Fate Therapeutics Q1 2024 GAAP EPS $(0.47)...
05/09/2024 20:05:49

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.47) per share which met the analyst consensus estimate. This i...

fate-therapeutics-treats-first-lupus-patient-in-phase-1-study-of-ft819-car-t-cell-therapy
Fate Therapeutics Treats First Lupus Patie...
05/09/2024 12:33:33

forecasting-the-future-8-analyst-projections-for-fate-therapeutics
Forecasting The Future: 8 Analyst Projecti...
05/06/2024 16:00:41

wedbush-reiterates-neutral-on-fate-therapeutics-maintains-7-price-target
Wedbush Reiterates Neutral on Fate Therape...
05/06/2024 12:23:57

Wedbush analyst David Nierengarten reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $7 price target.

fate-therapeutics-announces-presentation-of-ft522-preclinical-data-for-autoimmune-diseases-in-late-breaking-abstract-at-asgct-annual-meeting-adr-technology-incorporated-into-ft522-induces-functional-persistence-and-eliminates-alloreactive-host-immune-cells-in-sle-donor-pbmcs
Fate Therapeutics Announces Presentation O...
05/03/2024 20:31:26

Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Techn...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION